

## OPEN

# Reduced $^{123}\text{I}$ Ioflupane Binding in Bilateral Diabetic Chorea Findings With $^{18}\text{F}$ FDG PET, $^{99\text{m}}\text{Tc}$ ECD SPECT, and $^{123}\text{I}$ MIBG Scintigraphy

Kenichiro Sato, MD,\* Ayumi Hida, MD, PhD,\* Masashi Kameyama, MD, PhD,†  
Miyako Morooka, MD, PhD,† and Sousuke Takeuchi, MD, PhD\*

**Abstract:** We report a 64-year-old man with diabetic chorea whom we investigated with dopamine transporter SPECT,  $^{18}\text{F}$  FDG PET,  $^{99\text{m}}\text{Tc}$  ethylcysteinate dimer (ECD) SPECT, and  $^{123}\text{I}$  metaiodobenzylguanidine (MIBG) scintigraphy. Dopamine transporter SPECT revealed reduced  $^{123}\text{I}$  ioflupane binding in the bilateral striatum.  $^{18}\text{F}$  FDG PET showed metabolic dysfunction in the bilateral striatum, as shown in earlier studies.  $^{99\text{m}}\text{Tc}$  ECD SPECT revealed reduced brain perfusion in the bilateral caudate nucleus and putamen.  $^{123}\text{I}$  MIBG scintigraphy revealed no cardiac sympathetic nerve dysfunction. Our case suggests a possible nigrostriatal presynaptic dopaminergic involvement in diabetic chorea.

**Key Words:** diabetic chorea,  $^{123}\text{I}$  ioflupane, dopamine transporter SPECT,  $^{18}\text{F}$  FDG PET,  $^{123}\text{I}$  MIBG scintigraphy

(*Clin Nucl Med* 2016;41: 481–482)

Received for publication October 20, 2015; revision accepted February 1, 2016. From the \*Department of Neurology, and †Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.

Conflicts of interest and sources of funding: This study is supported by a grant from the National Center for Global Health and Medicine (to M.K.).

Correspondence to Ayumi Hida, MD, PhD, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. E-mail: ayumi-hida@umin.ac.jp.


Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

ISSN: 0363-9762/16/4106-0481

DOI: 10.1097/RLU.0000000000001202

## REFERENCES

1. Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. *Lancet Neurol*. 2006; 5:589–602.
2. Tossi-Bolt L, Hoffmann SM, Kemp PM, et al. Quantification of [ $^{123}\text{I}$ ]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. *Eur J Nucl Med Mol Imaging*. 2006;33:1491–1499.
3. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. *J Neurol Neurosurg Psychiatry*. 2010;81:5–12.
4. Hosokawa S, Ichiya Y, Kuwabara Y, et al. Positron emission tomography in cases of chorea with different underlying diseases. *J Neurol Neurosurg Psychiatry*. 1987;50:1284–1287.
5. Hsu JL, Wang HC, Hsu WC. Hyperglycemia-induced unilateral basal ganglion lesions with and without hemichorea. A PET study. *J Neurol*. 2004; 251:1486–1490.
6. Abe Y, Yamamoto T, Soeda T, et al. Diabetic striatal disease: clinical presentation, neuroimaging, and pathology. *Intern Med*. 2009;48:1135–1141.
7. Oh SH, Lee KY, Im JH, et al. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study: a meta-analysis of 53 cases including four present cases. *J Neurol Sci*. 2002; 200:57–62.
8. Belcastro V, Pierguidi L, Tambasco N, et al. Decreased contralateral putamen [ $^{123}\text{I}$ ]FP-CIT SPECT uptake in hyperglycemic hemichorea-hemiballismus. *Eur Neurol*. 2011;65:307–308.
9. Booth TC, Nathan M, Waldman AD, et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2. *AJNR Am J Neuroradiol*. 2015;36:236–244.



**FIGURE 1.** We present a 64-year-old man with subacute left-side dominant bilateral choreic movement (diabetic chorea) evaluated using a combination of dopamine transporter SPECT,  $^{18}\text{F}$  FDG PET,  $^{99\text{m}}\text{Tc}$  ethylcysteinate dimer ( $^{99\text{m}}\text{Tc}$  ECD) SPECT, and  $^{123}\text{I}$  metaiodobenzylguanidine (MIBG) scintigraphy. We diagnosed him with diabetic chorea because of poorly controlled diabetes mellitus (HbA1c 13%–18%) and brain MRI showing pathognomonic hyperintensity on T1-weighted imaging in the bilateral caudate nucleus and putamen and right-side external segment of the globus pallidus (A). No significant abnormality on T2- (B) and T2\*-weighted images (C) was found in the corresponding area. No significant old infarction or other differential diagnoses for chorea were identified.<sup>1</sup> Dopamine transporter SPECT showed bilaterally and right-side dominant reduced  $^{123}\text{I}$  ioflupane binding in the caudate nucleus and putamen (D). The specific binding ratio<sup>2</sup> was 1.22 on the right and 1.36 on the left side (ELEGP was used as a collimator, and no scatter correction or attenuation correction was applied). The asymmetry dopamine transporter SPECT in diabetic chorea index (AI) of ioflupane binding was 10.7%, revealing a decline predominantly on the right side. This was consistent with the contralateral dominance of the chorea. No confounding medication for the evaluation with dopamine transporter SPECT was identified.<sup>3</sup> Brain  $^{18}\text{F}$  FDG PET revealed decreased glucose metabolism (E) in the corresponding area, similar to the dopamine transporter SPECT, suggesting regional dysfunction in the bilateral striatum. There was no significant left-to-right difference in striatal  $^{18}\text{F}$  FDG PET uptake, with an AI of 2.7%.  $^{99\text{m}}\text{Tc}$  ECD SPECT revealed reduced brain perfusion in the bilateral caudate nucleus, putamen, and thalamus (F).  $^{123}\text{I}$  MIBG scintigraphy showed no reduction in the H/M ratio, with 4.95 in the early phase and 5.03 in the late phase (G, late phase). We assumed that a low accumulation in the mediastinum caused this high H/M ratio. Treatment with dopamine antagonist and blood glucose control relieved most choreic symptoms within 4 weeks, and we are now successfully reducing his dopamine antagonist dose. Reduced glucose metabolism was found in the bilateral putamen and caudate nucleus in the  $^{18}\text{F}$  FDG PET in our patient, suggesting regional striatal dysfunction. This was consistent with earlier studies on diabetic chorea.<sup>4–7</sup> Several theories regarding the underlying pathology of diabetic chorea have been proposed, including petechial hemorrhage,<sup>7</sup> metabolic abnormality because of hyperglycemia,<sup>5,7</sup> patchy striatal necrosis associated with vasculopathy,<sup>6</sup> and transient ischemia.<sup>7</sup> No conclusion has been reached to date. The only earlier report using dopamine transporter SPECT with hyperglycemic hemichorea-hemiballismus<sup>8</sup> revealed decreased  $^{123}\text{I}$  ioflupane binding in the striatum as was observed in our case. Cardiac imaging with  $^{123}\text{I}$  MIBG scintigraphy in our case revealed normal  $^{123}\text{I}$  MIBG uptake by the cardiac sympathetic nerve, suggesting that coexisting Parkinson's disease, Lewy body disease, diabetic sympathetic nerve dysfunction, or heart failure were unlikely. This suggests nigrostriatal dopaminergic involvement: presynaptic neuronal terminal dysfunction, reduced density of nerve terminals, or reduced density of dopamine transporter is conceivable.<sup>8,9</sup>